Literature DB >> 16783575

The strange case of TGN1412.

L Farzaneh, N Kasahara, F Farzaneh.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16783575     DOI: 10.1007/s00262-006-0189-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  7 in total

Review 1.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

2.  Supra-physiological efficacy at GPCRs: superstition or super agonists?

Authors:  Christopher J Langmead; Arthur Christopoulos
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 3.  Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma.

Authors:  Matthew Mansh
Journal:  Yale J Biol Med       Date:  2011-12

4.  Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.

Authors:  Zvi Teitelbaum; Thierry Lave; Jan Freijer; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

5.  The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo.

Authors:  Milica Vukmanovic-Stejic; Elaine Agius; Nicola Booth; Padraic J Dunne; Katie E Lacy; John R Reed; Toni O Sobande; Steven Kissane; Mike Salmon; Malcolm H Rustin; Arne N Akbar
Journal:  J Clin Invest       Date:  2008-10-01       Impact factor: 14.808

6.  The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity.

Authors:  Elisabeth Ersvaer; Astrid Olsnes Kittang; Peter Hampson; Kristoffer Sand; Bjørn Tore Gjertsen; Janet M Lord; Oystein Bruserud
Journal:  Toxins (Basel)       Date:  2010-01-22       Impact factor: 4.546

Review 7.  The growth and potential of human antiviral monoclonal antibody therapeutics.

Authors:  Wayne A Marasco; Jianhua Sui
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.